REGN3479

REGN3479 is a Regeneron-developed monoclonal antibody now entering clinical use as part of the first authorised therapeutic trial in the current Bundibugyo ebolavirus outbreak. It is paired with MBP134, a two-antibody cocktail, in the treatment Arm of the protocol. WHO Disease Outbreak News 607 (13 June) attributed the trial design to DRC and Uganda national leadership and community consultation, with ethics-committee and regulatory review still pending at time of reporting.

Monoclonal antibodies are laboratory-manufactured proteins that mimic the immune system's natural response: REGN3479 is engineered to bind to a specific surface structure on the Bundibugyo ebolavirus, blocking the virus from entering human cells. It is distinct from Regeneron's licensed product Inmazeb, a three-antibody cocktail approved by the US FDA in 2020 for Zaire ebolavirus only; Inmazeb has no established efficacy against the Bundibugyo species. REGN3479 was developed specifically targeting Bundibugyo antigenic characteristics, which differ sufficiently from Zaire that a separate antibody design was required.

The significance of REGN3479 entering trial lies in the gap it is filling. For weeks the outbreak ran with no treatment to offer patients confirmed with Bundibugyo Ebola, after the standard Zaire treatments (Inmazeb, Ebanga) were found ineffective against this species. By mid-July 2026, roughly 60 patients had enrolled across the trial's three arms (MBP134, REGN3479, obeldesivir), with results expected around September or October per Africa CDC; no efficacy data has yet been published. Whether REGN3479 achieves licensure depends entirely on the clinical data this trial generates. A haemorrhagic-fever trial conducted in an active, insecure conflict zone produces evidence slowly, but the drug is now being dosed to patients with no alternative.